

Allegiance Product Spotlight

Welcome to Allegiance's new product spotlight emails!

Each month we will feature one of our preferred vendor partners and their products and programs.

Scroll down to learn more about Embarc and how they would benefit your employees and their families.



Embarc Benefit Protection[®]

EMBARC BENEFIT PROTECTION[®]

Simple. Affordable. Predictable.


The high cost of gene therapies: a challenge in need of predictable pricing

Is your plan ready for a million-dollar claim?

Life-changing and potentially curative gene therapy medicines, which are used to treat patients with a genetic disease, offer great promise for patients and their families. However, the high prices of these medicines - sometimes \$2M+ - threaten access for the patients who may benefit.

With more gene therapies and eligible patients, there is a higher likelihood of a 'lightning strike' claim.

Gene Therapy Market Size³



IN THE NEXT FEW YEARS
the FDA anticipates approving
20 gene and cell therapies.¹



THE GENE THERAPY INDUSTRY
is projected to achieve a global
market size of \$15.68 billion
by 2030.²

A pathway for affordable access to expensive cures

Embarc Benefit Protection, a first of its kind solution, addresses a critical need facing the entire health care system by providing simple, affordable and predictable access to potentially curative treatments to those who need it.

The program brings together the health services, medical benefit management and specialty pharmacy expertise of Express Scripts®, PBM, eviCore®, Accredo®, and CuraScript® SD. Together with participating plans, we can:

- + **Improve access** to life-changing and potentially life-altering therapies for members
- + **Shield plans** from the price shock of suddenly paying for million-dollar therapies
- + **Create cost predictability** for your plan via a set price of \$0.99 per member, per month. Once plans have protected their member population through Embarc Benefit Protection, if a patient seeks one of the included gene therapies, they won't pay any out-of-pocket medication costs**
- + **Provide additional value** through an annual refund that may be available based on overall program claims paid vs. anticipated utilization
- + **Connect members** with best-in-class providers and support them on their journey

Embarc Benefit Protection is currently priced at \$0.99 PMPM

Price evaluated throughout the year, subject to change at any time as drugs are added

Reach out to your Allegiance Account Team to learn more!

The future of embarc benefit protection

New gene therapies will be evaluated for inclusion in the program as they emerge and receive FDA approval. Our focus is providing your plan with appropriate clinical and financial management for gene therapies as quickly as we can once new drugs come to market.

Our proven clinical and supply chain models give us a leading position to pioneer these kinds of solutions, the ability to exclusively manage unique therapies and the experience in caring for patients who take them.



For more information about **Embarc Benefit Protection®**, to learn what drugs are included and how to bring these therapies to those who need them, please visit our [Embarc Benefit Protection](#) solution page on [Evernorth.com](#) or contact your account representative.

* To review all of the drugs included in the Embarc Benefit Protection program, please visit the webpage here.

** If a member is enrolled in a "high deductible health plan" and has not met their deductible for that plan year, there may be out of pocket costs associated.

1. FDA Statement from Commissioner of Food and Drug Administration Scott Gottlieb M.D. on Jan. 19, 2019. Accessed 8/15/2022 at: <https://www.fda.gov/news-events/pressannouncements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics>
2. Source: Research and Markets. Accessed 8/18/2022 at: Global Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Cancer, Orthopedic), Application (Clinical, Commercial), End User (Pharma & Biotech, Academia) - Forecast to 2026 ([researchandmarkets.com](https://www.researchandmarkets.com))
3. Precedence Research, Accessed 8/18/2022 at: Gene Therapy Market Size, Growth, Trends, Report 2021-2030 ([precedenceresearch.com](https://www.precedenceresearch.com))

Not interested in Allegiance product updates?

If you no longer wish to receive these Vendor Spotlight emails, please reach out to your Account Executive to be removed from this distribution list.

If you unsubscribe from this email via the link below, you will no longer receive any emails from Allegiance, including important compliance updates and other urgent notices.

2806 Garfield St. P.O. Box 3018 | Missoula, MT 59806-3018
www.AskAllegiance.com

Allegiance Benefit Plan Management | 2806 S. Garfield St., P.O. Box 3018, Missoula, MT 59806

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by hrproductupdate@alert.askallegiance.com powered by



Try email marketing for free today!